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ABSTRACT
Objective: The patent expiry of a number of biological
medicines and the advent of biosimilars raised the
expectations of healthcare commissioners that
biosimilars would reduce the high cost of these
medicines and produce potential savings to the NHS.
We aimed to examine the prescribing pattern of
different growth hormone preparations (ready to use
and reconstitution requiring) in primary and secondary
care in England to determine relative rates of decrease
or increase and identify the possible factors influencing
prescribing following the introduction of biosimilar
growth hormone in 2008.
Design: Longitudinal observational study.
Setting and data sources: Primary care prescribing
cost and volume data was derived from the NHS
business services authority website, and for secondary
care from the DEFINE database, between April 2011
and December 2015.
Outcomes: Quarterly prescribing analysis to examine
trends and measure the relationship between usage
and price.
Results: Expenditure and usage of growth hormone in
primary care decreased by 17.91% and 7.29%,
respectively, whereas expenditure and usage in
secondary care increased by 68.41% and 100%,
respectively, between April 2011 and December 2015.
The usage of reconstitution requiring products
significantly declined in primary care (R²=0.9292) and
slightly increased in use in secondary care (R²=0.139).
In contrast, the usage of ready-to-use products
significantly increased in use in primary (R²=0.7526)
and secondary care (R²=0.9633), respectively. Weak or
no correlation existed between the usage and price of
growth hormone preparations in primary and
secondary care.
Conclusions: The price of growth hormone products
was not the key factor influencing the prescribing of
the biological medicines. The main driver for specific
product selection was the ease of use and the number
of steps in dose preparation. Prescribers appear to be
taking into account patient preferences rather than cost
in their prescribing decisions.
INTRODUCTION
Biological medicines can be deﬁned as bio-
technological products whose active ingredi-
ent is developed from living cells by one or
more of recombinant DNA, controlled gene
expression and antibody production
methods.1 These medicines represent an
advance in the treatment of patients with
chronic and life-threatening diseases such as
diabetes, growth hormone deﬁciency and
cancer.2 Biological medicines tend to be
expensive compared with conventional
drugs, mainly due to the cost of research and
development and their complicated biosyn-
thesis and handling techniques.3 For
example, remicade (inﬂiximab) costs
£12 584 per year per patient for the treat-
ment of Crohn’s disease.4 As a consequence,
they potentially place a heavy burden on
healthcare budgets even in developed coun-
tries with high resources.5 In a free at the
point of need health system funded through
general taxation, such as the UK NHS, there
is always pressure to remain within budget
and provide value for money for tax payers.6
According to the Health and Social Care
Information Centre report in 2015, the
expenditure on medicines in England was
£15.5 billion with hospital expenditure
growing at a higher rate than primary care.7
The Five Year Forward View of the NHS
England predicted a budget deﬁcit of nearly
£30 billion a year by 2020–2021 if the increas-
ing demand was met by no further annual
Strengths and limitations of this study
▪ This study includes cost and volume analysis of
all available growth hormone preparations in
England.
▪ The study analyses longitudinal observational
data set reflecting ‘real life’ prescribing in
primary and secondary care.
▪ The analysis shows which factors drive prescrib-
ing of growth hormone.
▪ Time period for analysis was limited to 5 years.
▪ Segmented regression of interrupted time series
analysis of the data was considered but cannot
be applied.
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efﬁciencies and funding remained ﬂat in real terms.8
NHS Healthcare policymakers’ aim to reduce the acqui-
sition cost of the drugs without affecting the clinical
outcome by increasing the uptake of less expensive
generic alternatives to branded medicines.9
The patent expiry of a number of biological medicines
and the establishment of regulatory frameworks by the
European Medicines Agency to register similar bio-
logical medicines termed ‘biosimilars’ raised the expec-
tations of healthcare commissioners that biosimilars
would reduce the high cost of these medicines and
produce potential savings to the NHS. The UK is a rela-
tively large market for biological and generic medicines,
so represents a potentially attractive market for the biosi-
milars manufacturers.10 Recent data have revealed that
the uptake of biosimilars in the UK is low compared
with Germany and Sweden.11 Possible reasons behind
this low uptake were healthcare prescribers and patients
concerns regarding quality, safety and efﬁcacy of biosimi-
lars and brand loyalty.12
Human recombinant growth hormone is a biological
medicine where a biosimilar has been available since
2006.13 An IMS Health report in 2014 showed that the
uptake of biosimilar growth hormone varies considerably
across the different European markets, with highest use
in Poland (99%) and lowest in Norway (3%) and the
UK (5%). In Poland, the implementation of a strict ten-
dering procurement system has resulted in the evolution
of growth hormone biosimilar market share.11 14 In
2015, growth hormone preparations cost £35 742 128
which represent 0.385% of the overall medicine bill in
primary care.7
Although the concept of generics and biosimilars is
the same, biosimilars cannot be considered generics,
since they are similar but not identical to the branded
biologics due to the high molecular weight and com-
plexity of biologics and the difference in synthesis
process.15 This has been recognised by the European
Medicine Agency (EMA) in speciﬁc legislation for biosi-
milars approval.16 The UK Medicines and Healthcare
products Regulatory Agency (MHRA) guidance on biosi-
milars is that products should not be assumed to be
identical due to the high molecular weight and struc-
tural differences between biological medicines. Thus,
biological medicines and biosimilars are prescribed by
brand names rather than by their International
Non-propriety Name.17 UK policymakers may have
anticipated that the lower price of biosimilars compared
with branded biological medicines (15–30%) would lead
to a rapid uptake in the same way as conventional small
molecule generic medicines, even though the price dif-
ferential is far greater for generic small molecule medi-
cines (50–90%).18 The high unit cost of biological
medicines means that the small percentage price differ-
ential could result in signiﬁcant annual savings.19 The
extent to which savings on prescribing for conventional
small molecule medicines can be realised is a function
of multifactorial inﬂuences on prescribing in the UK.20–
22 It is not clear whether the same inﬂuences which
apply to generic medicines are universally applicable to
biological medicines. Since 2006, the EMA has approved
23 biosimilars in different therapeutic areas, including
growth hormone, erythropoietins, granulocyte-colony
stimulating factors, monoclonal antibody and insulin.
The European experience during this 10 years identiﬁed
that the uptake and market penetration of potential bio-
similar depend on therapeutic area, geographic area
and patient acceptance. The uptake and market pene-
tration of biosimilars are also governed by price varia-
tions, local market dynamics, competitors, stakeholder
knowledge and experience with products and marketing
efforts by companies.23
The main objectives of this study were to undertake a
detailed analysis of the pattern of use of human recom-
binant growth hormone in primary and secondary care
settings in England and to determine possible factors
inﬂuencing its prescribing. A priori hypothesis was set,
that, similar to generic medicines, price would be the
dominant inﬂuencing factor in the use of these
medicines.
METHODS
Data source
The study was a retrospective analysis of primary and sec-
ondary care usage of growth hormone in England.
Primary care monthly prescription cost analysis data were
derived from the NHS business services authority
website,24 for prescriptions dispensed in primary care in
England from April 2011 to December 2015. Monthly sec-
ondary care data were taken from DEFINE Software for
2011–2016 since this prescribing database did not exist
before April 2011. DEFINE Software is a NHS prescribing
database of medicines usage in ∼120 hospitals (covering
over 90% of NHS hospitals throughout the UK including
Specialist Centres and Mental Health Trusts) who sub-
scribe to the software package.25 Data were at gross
national level not at institutional or patient level. The
volume comparator was the deﬁned daily dose (DDD),
deﬁned by the WHO as the mean maintenance daily dose
of a medicine for its principal indication in adults. The
DDD index for growth hormone is 2 international units.26
Primary care data were the number of items issued and
amount of drug in units. This was converted into DDDs
using the following formula:
Drugusage ðDDDsÞ ¼ ðitems issued
 amount of drug per itemÞ=DDD
Secondary care data were already available in DDDs.
Prices of the individual preparations were expressed as
price per DDD (£/DDD). Primary care prices were the
basic price of a drug excluding value-added tax (VAT)
(the price listed in the national Drug Tariff or in stand-
ard price lists). Secondary care prices were the average
net prices for different trusts throughout the UK, includ-
ing VAT.
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Statistical analysis
Regression analyses were used to understand and
explore the association (relation) between the inde-
pendent variables and the dependent variable, and the
forms of these relationships.27 28
Prescribing trends were examined for growth
hormone in primary and secondary care over the period
April 2011–December 2015. Linear regression analyses
were used with a quarter (3 months) as the independent
variable and prescription DDD as the dependent vari-
able, using quarterly data from each in primary and sec-
ondary care. The regression coefﬁcient values were
divided by the baseline prescription DDD (in April
2011) to calculate the average quarterly percentage
increase or decrease in prescribing of growth hormone.
Correlation analyses were used between prescription
DDD and price/DDD, using quarterly data from each in
primary and secondary care. All calculations were per-
formed using Microsoft Excel 2013 and SPSS V.21.
RESULTS
Pricing and expenditure
In primary care, prices of branded growth hormone pre-
parations did not change between April 2011 and
December 2015 with the exception of Genotropin pre-
parations which decreased by 25%. Biosimilar growth
hormone (Omnitrope preparations) prices decreased by
15% over this period (table 1). Over the same time
period, there were higher price reductions in secondary
care, including all Genotropin preparations, Humatrope
Cart, Norditropin SimpleXx, Omnitrope SurePal and
Zomacton Inj (table 1).
Expenditure on growth hormone preparations in
primary care in England decreased by 17.91% between
April 2011 and December 2015, whereas expenditure in
secondary care increased by 68.41% during the same
period.
Volume of usage
Growth hormone usage in primary care declined from
764 877 DDDs in the second quarter 2011 to 709 054
DDDs in the fourth quarter 2015. Regression analysis
indicates that this decline of on average 0.45% per
quarter (95% CI 0.70% to 0.21%) is statistically signiﬁ-
cant. Genotropin Cart, Norditropin SimpleXx and
Saizen Click.easy dominated the growth hormone
market by volume, accounting for 30%, 24% and 17.5%,
respectively, of prescribed growth hormone in the
second quarter 2011 (ﬁgure 1). By the fourth quarter
2015, Genotropin Cart, Norditropin SimpleXx still had
the highest share of the growth hormone market at 22%
for both, but Saizen Cart had replaced Saizen Click.easy
at 14.5% (ﬁgure 1).
In contrast to primary care, secondary care usage of
growth hormone doubled from 152 457 DDDs in the
second quarter 2011 to 304 443 DDDs in the fourth
quarter 2015 representing a statistically signiﬁcant rise of
on average 5.8% (95% CI 4.71% to 6.89%) per quarter.
As in primary care, Genotropin Cart and Norditropin
SimpleXx dominated the growth hormone market by
volume, accounting for 18% and 23%, respectively, of
prescribed growth hormone in the second quarter 2011.
By the fourth quarter 2015, Genotropin Cart had
decreased to 12%, Norditropin SimpleXx increased
slightly to 25%, but Omnitrope Cart and Saizen Cart
also accounted for 11% and 12% of the market, respect-
ively (ﬁgure 2).
The correlation analysis between price per DDD and
product usage in primary care revealed that for
Norditropin NordiFlex, Saizen Cart and Saizen Click.
easy, there was no correlation. For Genotropin Cart,
there was an intermediate positive correlation
(R²=0.5023), and for Genotropin MiniQuick,
Humatrope Cart, Norditropin SimpleXx and Zomacton
Inj, there were weakly positive correlation (R²=0.1081,
Table 1 Change in price/DDD (in GB pounds) of growth hormone in primary and secondary care between April 2011 and
December 2015
Primary care Secondary care
Drug name 2011 2012 2013 2014 2015 % Dif. 2011 2012 2013 2014 2015 % Dif.
Genotropin Cart 15.45 11.76 11.59 11.59 11.59 −25 18.55 15.38 13.4 13.4 13.4 −27.75
Genotropin GoQuick 15.45 11.76 11.59 11.59 11.59 −25 18.55 13.91 13.91 13.91 13.91 −25
Genotropin MiniQuick 15.45 11.76 11.59 11.59 11.59 −25 18.55 13.91 13.91 13.91 13.91 −25
Humatrope Cart 12.00 12.00 12.00 12.00 12.00 0 13.20 13.20 12.00 12.00 12.00 −9
Saizen Click.easy 15.45 15.45 15.45 15.45 15.45 0 18.55 18.55 18.55 18.55 18.55 0
Zomacton_Inj 13.28 13.28 13.28 13.28 13.28 0 15.94 15.94 13.95 13.95 13.95 −12.5
Norditropin NordiFlex 15.45 15.45 15.45 15.45 15.45 0 18.55 18.55 18.55 18.55 18.55 0
Norditropin SimpleXx 14.18 14.18 14.18 14.18 14.18 0 17.02 17.02 15.17 14.55 14.55 −14.5
NutropinAq Cart 13.53 13.53 13.53 13.53 13.53 0 14.37 14.37 15.34 15.34 15.34 6.75
Omnitrope Cart* 11.69 11.69 11.69 11.69 9.83 −16 11.52 11.52 11.52 11.52 11.52 0
Omnitrope SurePal*† 11.56 11.56 9.83 −15 13.46 10.92 10.92 −19
Saizen Cart 15.45 15.45 15.45 15.45 15.45 0 18.55 18.55 18.55 18.55 18.55 0
*Omnitrope and Omnitrope SurePal are growth hormone biosimilars.
†Omnitrope SurePal was marketed in June 2013 in secondary care and October 2013 in primary care.
% Dif., percentage of difference between 2011 and 2015 price/DDD.
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0.075, 0.2313 and 0.0006, respectively). For remaining
products, there were weakly negative correlations
(NutropinAq Cart R²=0.2066, Omnitrope Cart
R²=0.0764, Omnitrope SurePal R²=0.3614), with the
exception of Genotropin GoQuick, there was an inter-
mediate negative correlation.
In secondary care, a similar diverse pattern of correl-
ation between price/DDD and product usage was seen.
Norditropin NordiFlex and Omnitrope Cart showed no
correlation. For Genotropin GoQuick, NutropinAq Cart
and Saizen Cart, there were weakly positive correlation
(R²=0.2535, 0.0873, 0.0004, respectively). For remaining
products, there were weakly negative correlations
(Genotropin Cart R²=0.0128, Genotropin MiniQuick
R²=0.1622, Humatrope Cart R²=0.0155, Omnitrope
SurePal R²=0.4973 and Zomacton Inj R²=0.3766), with
the exception of Norditropin SimpleXx, there was an
intermediate negative correlation.
Table 2 summarises the main characteristics of recon-
stitution requiring agents and ready-to-use growth
hormone preparations. Figure 3 shows the usage trends
for products requiring reconstitution and those in a
ready-to-use formulation in primary and secondary care
settings. The usage of products requiring reconstitution
(Genotropin Cart, Genotropin GoQuick, Genotropin
MiniQuick, Humatrope Cart, Saizen Click.easy and
Zomacton Inj) all showed a clear decline in use in
primary care (R²=0.9292) and a slight increase in use in
Figure 1 Quarterly usage of growth hormone preparations in primary care between April 2011 and December 2015. DDD,
defined daily dose.
Figure 2 Quarterly usage of growth hormone preparations in secondary care between April 2011 and December 2015. DDD,
defined daily dose.
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secondary care (R²=0.139). In stark contrast, the usage
of ready-to-use products (Norditropin NordiFlex,
Norditropin SimpleXx, NutropinAq Cart, Omnitrope
Cart, Omnitrope SurePal and Saizen Cart) showed a
very clear increase in use in primary and secondary care
(R²=0.7526) and (R²=0.9633), respectively.
Figure 4 shows that in primary care, the usage of ﬁve
out of six ready-to-use agents increased between 2011
and 2015 irrespective to the price. The usage of four of
six of reconstitution requiring agents decreased during
the same period, although their prices have decreased.
Figure 5 shows that in secondary care that the usage of
all ready-to-use agents increased between 2011 and 2015
irrespective of price. The usage of three out of six recon-
stitution requiring agents increased during the same
period when their prices decreased. The usage of
remaining three reconstitution requiring agents
decreased, despite price reduction.
DISCUSSION
The long established principles of good prescribing
practice and medicines optimisation suggest that clini-
cians aim to prescribe to maximise effectiveness, minim-
ise risks and take into account the patients experience.29
At the same time, in a health system free at the point of
Table 2 Growth hormone preparations characteristics
Reconstitution requiring agent Ready-to-use agents
Agent Description Agent Description
Genotropin
Cart
Cartridge needed, needs fridge after
reconstitution, dose cannot preset
NutropinAq
Cart
Cartridge needed, needs fridge, dose cannot
preset
Genotropin
GoQuick
Prefilled, needs fridge after reconstitution Norditropin
NordiFlex
Prefilled, dose cannot preset
Genotropin
MiniQuick
Prefilled syringe, single dose,
preservative-free, portable, can be kept
outside the fridge before use
Norditropin
SimpleXx
Cartridge needed, dose cannot preset, can be
kept at room temperature for 3 weeks after first
use, auto-injector
Humatrope
Cart
Cartridge needed, needs fridge before
and after reconstitution, dose cannot
preset
Omnitrope
Cart
Cartridge needed, needs fridge, dose cannot
preset
Zomacton Inj Needle-free, phial needed, may cause
skin reaction, dose cannot be preset
Omnitrope
SurePal
Cartridge needed, needs fridge, dose preset,
hidden needle
Saizen Click.
easy
Automatic needle insertion, cartridge
needed, needs fridge during use, dose
cannot preset
Saizen Cart Electronic—automatic injector, dose preset,
records of dose history, hidden needle,
on-screen for instruction of use, control of
comfort parameters (injection depth, time,
speed), cartridge needed
Figure 3 Comparison between reconstitution requiring agents and ready-to-use agents in primary and secondary care between
April 2011 and December 2015. DDD, defined daily dose.
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need funded by general taxation, prescribers consider
relative costs of medicines and NHS policy and NICE
guidance while still respecting the patient’s choice.30 31
Balancing between these conﬂicting aims and recom-
mendations result in good prescribing to achieve
maximum effectiveness, minimum risk and cost,
although it is recognised that ﬁnancial and non-ﬁnancial
incentives may also be needed to encourage best
practice.32
In the UK, growth hormone prescribing follows a
shared care protocol between primary and secondary
care. In hospital, a consultant endocrinologist ﬁrst diag-
noses the patient requiring growth hormone. An endo-
crine specialist nurse demonstrates the available growth
hormone devices to the patient, then trains the patient
on the use of their chosen device. The patient is then
provided with an initial supply. The primary care
general practitioner (GP) continues prescribing growth
hormone for the patient in accordance with the local
agreed shared care protocol.33
In England, there are currently seven preparations of
growth hormone. Although these preparations differ in
their injecting device for the delivery of growth
hormone, these preparations are equal in terms of clin-
ical effectiveness.34 With the availability of such a variety
of preparations, endocrinologists and other healthcare
professionals prescribing growth hormone are being
asked to make some complex decisions regarding the
selection of the preparation for each patient. The latest
NICE guidelines in 2010 for treatment with growth
hormone stated that the product selection should be
based on a discussion between the prescriber and the
patient or the patients’ parents, taking into account the
advantages and disadvantages of each device. If more
than one option is suitable, the less expensive one
should be chosen.34
In this study, we classiﬁed growth hormone delivery
devices into reconstitution requiring agents and
ready-to-use agents. Ready-to-use agents were charac-
terised by fewer steps and time required for dose prepar-
ation by patients and potentially a reduction in user
errors that may occur during the reconstitution process.
Reconstitution can be quite complex since each prepar-
ation requires a special reconstitution kit. The cartridge
containing lyophilised growth hormone is reconstituted
using only the diluent syringe that accompanies the cart-
ridge. The diluent syringe is placed into the reconstitu-
tion kit, the needle cover of the diluent syringe is
removed and the cartridge inserted. When the diluent
needle is inserted inside the cartridge, the plunger of
the diluent is pushed until all the diluent is transferred
into the cartridge. The cartridge is then removed from
the kit, with gentle rotary movement (mixing) but not
shaking until the solution became clear.35
Figure 4 Usage versus price/
DDD of reconstitution requiring
agents and ready-to-use agents
of growth hormone preparations
in primary care. DDD, defined
daily dose.
Figure 5 Usage versus price/
DDD of reconstitution requiring
agents and ready-to-use agents
of growth hormone preparations
in secondary care. DDD, defined
daily dose.
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Studies have identiﬁed that premixed solution devices
(ready-to-use devices) are more acceptable to patients
and/or parents than reconstitution requiring devices.
The simplicity and the least steps required for prepar-
ation and administration of growth hormone doses are
considered among the most desirable attributes of
administration devices.36 37 Ready-to-use agents are asso-
ciated with less pain than reconstitution requiring
agents due to the higher concentration of these pro-
ducts and, therefore, smaller volumes of growth
hormone injected. Furthermore, added preservative and
buffer to the premixed solution of growth hormone
decrease the injection pain.38
Interestingly, the usage of the growth hormone market
leader in primary care Genotropin Cart decreased over
the study period, despite a 25% price reduction
(ﬁgure 1). Over the same time period, Saizen Cart
(ready-to-use agent) replaced Saizen Click.easy (reconsti-
tution requiring agent), although it was the same price
(ﬁgure 1). This challenges policy assumptions that
cheaper drugs will dominate. It also shows that perceived
preference may outweigh national guidance to select
lowest cost agents. The results have implications for those
considering effectiveness of implementation of national
guidance. Furthermore, the results have implications for
NHS budget mangers when they consider which medi-
cines to make available within local health economies.
The pattern of product usage in secondary care was
more diverse (ﬁgure 2). In this sector, Genotropin Cart
usage decreased, despite a 27.75% price reduction over
the study period (ﬁgure 2). The market leader in sec-
ondary care, Norditropin SimpleXx (ready-to-use
agent), grew only slightly, despite a 14.5% price reduc-
tion. Omnitrope Cart (the less expensive option) and
Siazen Cart (the most expensive option) (the
ready-to-use agents) increased their share of the second-
ary care market, although in both cases, the price did
not change. These ﬁndings suggest ease of use rather
than price is the key inﬂuence on the prescribing deci-
sion. Within the NHS in the UK, medicines are reim-
bursed differently in primary and secondary care. In
primary care, community pharmacies are reimbursed by
the government for the medicines they dispense at a
basic NHS price which is set nationally, whereas in hospi-
tals, the prices paid for medicines are negotiated with
manufacturers through regional and local contracting
processes. These discounts are sometimes offset since
hospital medicines attract VAT, whereas primary care
medicines do not. This means that the price of medi-
cines is often different in secondary care.
The analysis of price and product usage supports this
observation. A number of products in primary and sec-
ondary care showed no correlation between price and
production usage. Indeed, some showed a positive cor-
relation indicating that the higher price was associated
with higher use. A negative correlation would suggest
that price was inﬂuencing use. However, in primary and
secondary care, all the negative correlations were weak
R2<0.5, with the exception of Genotropin GoQuick in
primary care and Norditropin SimpleXx in secondary
care which were intermediate R2>0.5<0.75. This com-
plete diversity of correlations in both sectors indicates
price is not the driver for product use.
The use of ready-to-use agents increased in both
sectors during the study period (ﬁgure 3). This explains
the slight overall decrease in growth hormone in
primary care as it comprises a growth in the use of the
ready-to-use agents counteracted by a signiﬁcant
decrease in the use of the reconstitution requiring
agents. Furthermore, the overall growth in secondary
care comprises a signiﬁcant (almost tripling) growth in
the ready-to-use agents and a ﬂattening use of the recon-
stitution requiring agents (ﬁgure 3). Figure 3 also shows
that reconstitution requiring agents dominated until
2014, but were overtaken by ready-to-use agents. This is
perhaps a reﬂection of the more conservative rate of
change of prescribing patterns in the UK, since the
reconstitution requiring agents were available since
1987,39 whereas the ﬁrst ready-to-use agents only
became available in the UK in 2000 and the newer
devices from 2011 (Norditropin Nordiﬂex and Saizen
Cart were launched in 2011 and Omnitrope Surepal was
launched in 2013).40 41 This is supported in the litera-
ture, which has identiﬁed the UK market as one of the
slowest markets in Europe in taking up new medicines.42
Furthermore, stable patients will most likely have
remained on the product they were initiated on since if
all is well, patients and prescribers may be disinclined to
switch. Thus, given the nature of this therapy, it takes
time for new products to get market traction.
Figures 4 and 5 also suggest that the quantity or the
usage of growth hormone preparations is not price
dependent in primary and secondary care settings. The
usage of ready-to-use agents increased in both sector irre-
spective to the change in price (decreased or unchanged).
This suggests that the ease of use rather than price is
the key driver for growth hormone product selection in
primary and secondary care. The ﬁndings from this
study agree with previous studies of branded growth
hormone that outlined that the ease of use and conveni-
ence (premixed formulations) were the most important
product characteristics from patients’ perspective.37 43 44
This may have been because the patients are adolescents
who will be in full-time education and require formula-
tions which are quick and easy to use.
Previous literature on this subject has focused on
patient preferences in relation to speciﬁc devices. This
study focused on whether these preferences are trans-
lated into prescriber product selection. Implicitly, this
suggests that for growth hormone, prescribers, while fol-
lowing the principles of medicines optimisation take
more account of patient preferences than central guid-
ance on cost efﬁciency. This contrasts with other health
economies were mandated switching to growth hormone
biosimilar meant that 99% of prescribing was the less
expensive biosimilar.14
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Our study has several limitations; ﬁrst, the time period
for analysis was limited to 5 years as we wanted to
explore the usage of growth hormone in primary and
secondary care. We could only access monthly data for
primary and secondary care since 2011. Second, seg-
mented regression of interrupted time series analysis of
the data was considered, but growth hormone prices
change were not linked to a single point of time and
NICE guidance on growth hormone was not changed
during the study period. Visual analyses of ﬁgures 1 and
2 showed no abrupt change in the pattern of the usage
of growth hormone over the study period required for
this type of analysis.
CONCLUSION
This study has suggests that the price of growth
hormone products is not the key inﬂuencing factor in
the prescribing of biological medicines. The main driver
for speciﬁc product selection is the ease of use and
fewer steps in dose preparation. Prescribers are clearly
taking into account patient preferences rather than cost
in their prescribing decisions, in line with national
guidance.
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